RxDoctor Payments Data

Mark Williams, MD

Nephrology · Boston, MANPI 1184653891

Payments from drug & device makers

$34,555in general payments, 2019–2025

Across 49 payments — averaging $705.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$23K
  • Baxter Healthcare$7K
  • Bayer$2K
  • Fresenius USA Marketing, Inc.$1K
  • Vantive US Healthcare LLC$872
  • AstraZeneca$166
  • plus $266 from 3 others
$300in research payments, 2019–2025

Across 1 payment — averaging $300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$300

What the payments were for

  • Consulting fees$22,20864%
  • Speaking & faculty fees$6,50019%
  • Travel & lodging$3,39610%
  • Food & beverage$2,3727%
  • Education$780%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,555 in reported general payments places this provider in the 80th percentile of 339 nephrology providers in Massachusetts.

See all nephrology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$131,893
Medicare patients
244
Services billed
943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone86$121,646
VeltassaPatiromer Calcium Sorbitex20$43,846
FarxigaDapagliflozin Propanediol41$42,291
JardianceEmpagliflozin20$32,029
AuryxiaFerric Citrate12$17,450
LokelmaSodium Zirconium Cyclosilicate13$17,293
ProsolParenteral Amino Acid 20% No.171$9,291
Cinacalcet Hcl18$6,154
Paricalcitol33$5,985
Irbesartan114$4,530
Sevelamer Carbonate28$4,327
Calcitriol132$3,217
Labetalol Hcl50$1,528
Losartan Potassium97$1,081
Eplerenone13$1,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$1,891$121,64686 claims
AstraZenecaFarxiga, Lokelma$166$59,58454 claims
Akebia Therapeutics IncAuryxia$121$17,45012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 339 nephrology providers in Massachusetts.

Other nephrology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →